Business Description
D. Western Therapeutics Institute Inc
ISIN : JP3548740004
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.17 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 1.3 | |||||
Debt-to-EBITDA | -1.02 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -1.25 | |||||
Beneish M-Score | -3.3 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1 | |||||
3-Year EBITDA Growth Rate | -40.2 | |||||
3-Year EPS without NRI Growth Rate | -34.7 | |||||
3-Year FCF Growth Rate | -32.5 | |||||
3-Year Book Growth Rate | -18.6 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 31.14 | |||||
9-Day RSI | 30.51 | |||||
14-Day RSI | 33.81 | |||||
6-1 Month Momentum % | -32.83 | |||||
12-1 Month Momentum % | -57.37 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 19.32 | |||||
Quick Ratio | 18.24 | |||||
Cash Ratio | 13.6 | |||||
Days Inventory | 906.47 | |||||
Days Sales Outstanding | 104.74 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.2 | |||||
Shareholder Yield % | -0.44 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 91.27 | |||||
Operating Margin % | -213.29 | |||||
Net Margin % | -233.77 | |||||
FCF Margin % | -133.47 | |||||
ROE % | -82.77 | |||||
ROA % | -45.2 | |||||
ROIC % | -192.64 | |||||
3-Year ROIIC % | 972.74 | |||||
ROC (Joel Greenblatt) % | -409.15 | |||||
ROCE % | -48.63 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4.88 | |||||
PB Ratio | 2.71 | |||||
Price-to-Tangible-Book | 2.91 | |||||
EV-to-EBIT | -2.07 | |||||
EV-to-EBITDA | -2.07 | |||||
EV-to-Revenue | 4.89 | |||||
EV-to-FCF | -3.88 | |||||
Price-to-Median-PS-Value | 0.17 | |||||
Price-to-Net-Current-Asset-Value | 3.56 | |||||
Price-to-Net-Cash | 32 | |||||
Earnings Yield (Greenblatt) % | -48.08 | |||||
FCF Yield % | -24.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
D. Western Therapeutics Institute Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 2.871 | ||
EPS (TTM) (€) | -0.209 | ||
Beta | 0.73 | ||
Volatility % | 35.14 | ||
14-Day RSI | 33.81 | ||
14-Day ATR (€) | 0.005762 | ||
20-Day SMA (€) | 0.3408 | ||
12-1 Month Momentum % | -57.37 | ||
52-Week Range (€) | 0.266 - 0.915 | ||
Shares Outstanding (Mil) | 36.08 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
D. Western Therapeutics Institute Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
D. Western Therapeutics Institute Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
D. Western Therapeutics Institute Inc Frequently Asked Questions
What is D. Western Therapeutics Institute Inc(FRA:6DW)'s stock price today?
When is next earnings date of D. Western Therapeutics Institute Inc(FRA:6DW)?
Does D. Western Therapeutics Institute Inc(FRA:6DW) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |